Myriad Asset Management US LP Buys Shares of 6,045 SPDR S&P Biotech ETF $XBI

Myriad Asset Management US LP purchased a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 6,045 shares of the exchange traded fund’s stock, valued at approximately $737,000. SPDR S&P Biotech ETF makes up 1.2% of Myriad Asset Management US LP’s investment portfolio, making the stock its 18th biggest holding.

Several other hedge funds have also recently modified their holdings of XBI. AQR Capital Management LLC increased its holdings in SPDR S&P Biotech ETF by 77.1% during the first quarter. AQR Capital Management LLC now owns 4,978 shares of the exchange traded fund’s stock valued at $404,000 after buying an additional 2,167 shares during the period. Edgestream Partners L.P. bought a new position in SPDR S&P Biotech ETF in the second quarter worth approximately $526,000. Twin Peaks Wealth Advisors LLC purchased a new stake in SPDR S&P Biotech ETF during the second quarter worth $32,000. CW Advisors LLC lifted its holdings in SPDR S&P Biotech ETF by 2.3% during the second quarter. CW Advisors LLC now owns 22,517 shares of the exchange traded fund’s stock worth $1,867,000 after buying an additional 496 shares during the period. Finally, Marshall Wace LLP boosted its position in SPDR S&P Biotech ETF by 102.3% during the 2nd quarter. Marshall Wace LLP now owns 4,023 shares of the exchange traded fund’s stock valued at $334,000 after acquiring an additional 179,029 shares in the last quarter.

SPDR S&P Biotech ETF Stock Performance

Shares of NYSEARCA:XBI opened at $128.96 on Friday. SPDR S&P Biotech ETF has a 12-month low of $66.66 and a 12-month high of $132.09. The business’s fifty day simple moving average is $125.00 and its 200-day simple moving average is $118.38. The company has a market capitalization of $7.51 billion, a PE ratio of 11.47 and a beta of 0.93.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.